Abstract:<p>Greater understanding of tumour immunobiology has led to a new era of cancer treatment in which immuno-oncology (IO) therapies are used to boost anti-cancer immune responses. Prominent among these therapies are immune checkpoint inhibitors (ICIs), antibody-based drugs that can unleash the power of tumour-specific CD8 + T-cells. ICIs targeting the Programmed cell death protein 1 (PD-1) cell surface receptor or its ligand PD-L1 are particularly effective, with clinical studies reporting powerful and durable therapeutic impact against many cancer types, including melanoma and non-small cell lung cancer. ICIs have the potential to transform the landscape of cancer treatment, and their development was recognised by the award of the 2018 Nobel Prize in Physiology or Medicine to James Allison and Tasuku Honjo. However, the proportion of patients responding to anti-PD-1/PD-L1 monotherapy can be low. The next major challenge involves understanding and overcoming the innate and acquired resistance that prevents most patients from responding to PD-1/PD-L1 blockade. In this review, we outline the physiological function of PD-1 and its exploitation by developing tumours. We give an overview of current FDA-approved drugs targeting PD-1 or PD-L1 and summarise clinical progress so far. We then discuss key mechanisms thought to underpin resistance to PD-1/PD-L1 blockade, describing biomarkers that could allow patient responses to be predicted before treatment, and tracked once treatment has started. We also present clinical and pre-clinical combination therapies that have been developed to overcome resistance and which have the potential to substantially extend the therapeutic reach of these revolutionary drugs.</p>

Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome

Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment

Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)

Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy

Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle

Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade

Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?